Description: Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It offers AcoArt Orchid & Dhalia to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease; under clinical studies in nephrology for arteriovenous fistula stenosis and in neurology for vertebral atherosclerotic stenosis indications/applications; and under clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company also provides AcoArt Tulip & Litos, which is under registration process in China and Europe, and under preclinical studies in the United States in vascular surgery for below-the-knee artery disease indications/applications; and in pre-clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited is a subsidiary of CA Medtech Investment (Cayman) Limited.
Home Page: www.acotec.cn
Building No. 1
Beijing,
100176
China
Phone:
86 10 6787 2107
Officers
| Name | Title |
|---|---|
| Ms. Jing Li | Exec. Chairperson of the Board & CEO |
| Mr. Silvio Rudolf Schaffner | COO & Exec. Director |
| Dr. Ulrich Reinhold Speck | Chief Technology Officer |
| Ms. Hui Zhang | VP of Marketing & Sales |
| Mr. Chen Li | Joint Company Sec. |
| Ms. Ching Yi Li | Joint Company Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.4428 |
| Price-to-Sales TTM: | 16.2177 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 534 |